Xencor Regains CD20 x CD3 Bispecific T-Cell Engager
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/26/2026
- S&P 500, Nasdaq set for weekly fall as chip stocks slide
- SpaceX weighs Starlink mobile service to US consumers, FT reports
- U.S. chip stocks retreat after Apple price hikes stoke fears over AI trade
- Morgan Stanley flags Fed hike risk if unemployment drops below 4%
- UBS trims AI portfolio exposure to semis and hardware after recent rally
- Needham Starts NeoVolta (NEOV) at Buy
- TD Cowen: 'Sober View Suggests Structural Alcohol Risks Are Overblown'
- Two major earthquakes strike Venezuela, killing at least 32 and injuring hundreds
- Hertz cuts guidance, announces notes and stock offerings, shares sink
- Wall St ends mixed as tech megacap declines outweigh upbeat chip outlook
Xencor, Inc. (XNCR) PT Lowered to $31 at RBC Capital
June 14, 2024 6:25 AM EDTRBC Capital analyst Gregory Renza lowered the price target on Xencor, Inc. (NASDAQ: XNCR) to $31.00 (from $32.00) while maintaining a Outperform rating.
The analyst comments "This morning XNCR disclosed the company has regained plamotamab (CD20 x CD3) as partner Janssen will terminate its... More
